NQO2 (N-Ribosyldihydronicotinamide:Quinone Dehydrogenase 2)
A quinone oxidoreductase involved in detoxification, oxidative stress response, and cancer susceptibility.
Gene Information Card
| Symbol | NQO2 |
|---|---|
| Full Name | N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 6p25.2 |
| NCBI Gene ID | 4835 ncbi.nlm.nih.gov/gene/4835 |
| Ensembl ID | ENSG00000124588 |
| UniProt ID | P16083 |
| OMIM ID | 160980 |
| HGNC ID | 7856 |
| Aliases | QR2, DHQV, DIA6, NMOR2 |
Description
NQO2 encodes a cytosolic flavoprotein that catalyzes the two-electron reduction of quinones and their derivatives, using dihydronicotinamide riboside (NRH) as an electron donor. It plays a role in detoxification of xenobiotics, protection against oxidative stress, and modulation of cellular redox balance. NQO2 is also implicated in cancer susceptibility and neurodegenerative disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | NQO2 polymorphisms (e.g., rs1143684) alter enzyme activity, affecting detoxification of carcinogenic quinones and influencing cancer risk. | PMID: 15642721; COSMIC |
| Parkinson's disease | Reduced NQO2 activity may lead to accumulation of neurotoxic quinones, contributing to dopaminergic neuron degeneration. | PMID: 16123147; ClinVar |
| Alzheimer's disease | NQO2 is upregulated in affected brain regions; altered quinone metabolism may exacerbate oxidative damage. | PMID: 15159495 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.3 | Medium |
| Kidney | 9.8 | Medium |
| Heart | 6.5 | Low |
| Brain | 4.2 | Low |
| Lung | 3.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 15.2 | Hepatocellular carcinoma cell line |
| HEK293 | 8.7 | Embryonic kidney cells |
| SH-SY5Y | 5.4 | Neuroblastoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| rs1143684 (Ile104Val) | Missense | 0.15 (global) | Reduced catalytic activity; associated with altered cancer risk. |
| rs2071002 (3' UTR variant) | Regulatory | 0.20 (global) | May affect mRNA stability and expression levels. |
Mutation functional classification
Loss of Function (LOF)
rs1143684 (Ile104Val) reduces enzymatic activity, impairing quinone detoxification.
Gain of Function (GOF)
No well-characterized gain-of-function mutations reported.
Dominant Negative (DN)
Not described for NQO2.
View complete mutation data：
Gene Ontology (GO)
| • quinone binding | • oxidoreductase activity |
| • FAD binding | • identical protein binding |
| • cellular response to oxidative stress | • xenobiotic metabolic process |
Pathways
• Quinone detoxification
• NRH:quinone oxidoreductase pathway
Protein Summary
NQO2 is a 231-amino acid cytosolic flavoprotein that forms a homodimer. It uses NRH as a cofactor to reduce quinones, protecting cells from oxidative damage. The protein is expressed in multiple tissues, with highest levels in liver and kidney. Polymorphisms in NQO2 are associated with cancer susceptibility and neurodegenerative diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NQO2 Knockout HEK293 Cell Line | EDJ-KQ2186 | Human | 4835 | Details Get a Quote |
| NQO2 Knockout A-549 Cell Line | EDJ-KQ22407 | Human | 4835 | Details Get a Quote |
| NQO2 Knockout HCT 116 Cell Line | EDJ-KQ22408 | Human | 4835 | Details Get a Quote |
| NQO2 Knockout HeLa Cell Line | EDJ-KQ22409 | Human | 4835 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
